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Abstract
Background
The long-term treatment outcome of visceral leishmaniasis (VL) patients with HIV co-infec-
tion is complicated by a high rate of relapse, especially when the CD4 count is low. Although
use of secondary prophylaxis is recommended, it is not routinely practiced and data on its
effectiveness and safety are limited.
Methods
A prospective cohort study was conducted in Northwest Ethiopia from August 2014 to
August 2017 (NCT02011958). HIV-VL patients were followed for up to 12 months. Patients
with CD4 cell counts below 200/μL at the end of VL treatment received pentamidine prophy-
laxis starting one month after parasitological cure, while those with CD4 count�200 cells/μL
were followed without secondary prophylaxis. Compliance, safety and relapse-free survival,
using Kaplan-Meier analysis methods to account for variable time at risk, were summarised.
Risk factors for relapse or death were analysed.
Results
Fifty-four HIV patients were followed. The probability of relapse-free survival at one year
was 50% (95% confidence interval [CI]: 35–63%): 53% (30–71%) in 22 patients with CD4
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�200 cells/μL without pentamidine prophylaxis and 46% (26–63%) in 29 with CD4 <200
cells/μL who started pentamidine. Three patients with CD4 <200 cells/μL did not start pent-
amidine. Amongst those with CD4�200 cells/μL, VL relapse was an independent risk factor
for subsequent relapse or death (adjusted rate ratio: 5.42, 95% CI: 1.1–25.8). Except for
one case of renal failure which was considered possibly related to pentamidine, there were
no drug-related safety concerns.
Conclusion
The relapse-free survival rate for VL patients with HIV was low. Relapse-free survival of
patients with CD4 count <200cells/μL given pentamidine secondary prophylaxis appeared
to be comparable to patients with a CD4 count�200 cells/μL not given prophylaxis. Patients
with relapsed VL are at higher risk for subsequent relapse and should be considered a prior-
ity for secondary prophylaxis, irrespective of their CD4 count.
Author summary
Achieving parasitological cure at the end of visceral leishmaniasis (VL) treatment in HIV
co-infected patients does not assure definitive cure, as the disease will recur within a year
in many patients. In this cohort study, the probability of relapse-free survival at one-year
was 50% in all patients. The use of monthly pentamidine infusion for those with lower
CD4 counts (<200 cells/μL) at the time of VL cure appeared to result in a comparable
relapse-free survival rate to those patients with higher CD4 count (�200 cells/μL) who did
not receive secondary prophylaxis. On the other hand, patients with a history of previous
VL treatment (VL relapse) remained at high risk of relapse despite achieving CD4 count
�200 cells/μL at the end of the VL treatment. While all VL patients with HIV co-infection
may benefit from secondary prophylaxis, those with CD4 <200 cells/μL and previous his-
tory of treatment should be prioritized for secondary prophylaxis. New modalities for pre-
vention of VL relapse in HIV patients should also be explored.
Introduction
When visceral leishmaniasis (VL) occurs in HIV patients, it presents several challenges [1].
These include changes in clinical manifestations that may result in delayed diagnosis; changes
in immunological response to the infection that affect the performance of diagnostic tools; and
poor treatment response, in terms of low initial cure, relapse and mortality, due mainly to the
combined effects of both infections causing profound immunosuppression [2,3].
The anti-leishmanial medicines available cannot completely eradicate the Leishmania para-
sites from the body [4]. Even those patients who are declared parasitologically cured at the end
of treatment are, in reality, left with some parasites in the tissues that are not undetectable by
microscopy [5]. In immunocompetent individuals, these are contained by cell mediated
immunity, probably providing some degree of protection. However, in HIV patients, this
small number of remaining parasites continues to replicate resulting in relapse of disease [6],
which then becomes more difficult to cure. These patients tend to have a persistent infection
with flare-ups of clinical disease, described as active chronic disease [7]. Despite repeated treat-
ment courses, such patients remain poorly responsive to treatment and deteriorate in their
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clinical and immune status. This leads to a high rate of failure to both VL and HIV treatments,
and risk of death [8].
Hence, it is logical to introduce a maintenance therapy or secondary prophylaxis for this
group of patients, as is done for other opportunistic infections in HIV, to continually suppress
the multiplication of the parasite. Although secondary prophylaxis has been recommended in
some international guidelines [9,10], this is based on small studies from L infantum transmis-
sion in Europe [11,12]. In anthroponotic transmission regions like Eastern Africa, patients
with persistent Leishmania parasites may serve as reservoirs of infection. Their need for
repeated treatments with the limited available drugs increases the risk that they will be a source
of emergent drug-resistant parasites [13]. Thus, first line drugs used to treat leishmaniasis in
the region are not good options for use as secondary prophylaxis for fear of enhancing resis-
tance development.
The use of secondary prophylaxis for VL has not been routinely practiced in high endemic
regions such as Northwest Ethiopia. Previous studies have demonstrated that the relapse rate
of VL in HIV patients is 60–70% within a year of VL treatment [14,15]. Patients with low CD4
count and previous VL episodes were found to be at the highest risk of relapse. A recent pro-
spective cohort study in Northwest Ethiopia has demonstrated 71% relapse free survival at one
year among VL-HIV patients using pentamidine as a secondary prophylaxis for patients with
CD4<200 cells/μL or relapsed VL [16]. This is the only report on secondary prophylaxis for
VL in the region. The objective of the current study is to document the long-term treatment
outcomes of VL in HIV infected patients, namely the relapse-free survival, and to assess risk
factors for relapse or death for up to one year after treatment for VL. Pentamidine was used as
secondary prophylaxis for patients with CD4 cell count< 200 cells/μL after VL was success-
fully treated while those patients with CD4�200 cells/μL were followed without secondary
prophylaxis.
Methods
Study design
This was a prospective cohort study of parasitologically cured VL patients with HIV co-infec-
tion. It followed another randomised clinical trial (NCT02011958), that had a non-compara-
tive design to evaluate the efficacy and safety of two treatment regimens for VL in HIV co-
infected patients (AmBisome total dose of 40 mg/kg and Ambisome total dose of 30 mg/kg +
miltefosine 100mg/day/28days). In the preceding trial, one or two courses of the allocated
treatment were given until patients achieved parasitological cure. One course of treatment was
defined as the standard dose/duration of therapy with a specified anti-leishmanial drug e.g. a
total dose of 40 mg/Kg of Ambisome monotherapy or 30 mg/kg of Ambisome plus 28-day
course of miltefosine regimens. Patients who still had not reached cure after two cycles of VL
therapy received rescue treatment at the discretion of the treating physician. At the end of VL
therapy, patients who had a negative tissue microscopy result for Leishman-Donovan (LD)
bodies were eligible for this prospective cohort study.
Setting
The study was conducted in Northwest Ethiopia at two large leishmaniasis treatment centres:
the Leishmaniasis Research and Treatment Centre at University of Gondar Hospital, sup-
ported by Drugs for Neglected Diseases initiative; and the Abdurafi Health Centre Me´decins
Sans Frontières Leishmaniasis Treatment Centre. Both are referral centres for complicated
leishmaniasis cases.
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Each of these centres treats over 400 VL patients every year, of whom around 15–20% are
co-infected with HIV. Most are adult seasonal migrant workers who travel from highland
areas to work on large lowland farms where VL is endemic.
Participants
Patients were enrolled from 14th August 2014, and follow-up ended on 12th August 2016.
There were 55 patients who achieved parasitological cure with VL treatment(s) during the trial
preceding this study. One patient was subsequently lost to follow-up and the remaining 54
patients were included in this cohort study (Fig 1).
Sample size
This research aimed to study the long-term outcomes of VL patients with HIV co-infection
enrolled in the above-mentioned clinical trial. The sample size of the clinical trial was deter-
mined based on expected efficacy of the initial treatment, and as such provides a fixed sample
size for this cohort study as the number of patients surviving to negative parasitology post
treatment for VL. There were no pre-specified sample size calculations specifically for the
cohort study objectives reported here.
Intervention
Patients who achieved parasitological cure but remained with a CD4 count below 200 cells/μL
at the end of VL treatment were approached and consent was sought for pentamidine second-
ary prophylaxis. Patients with contraindications for pentamidine (renal impairment, diabetes,
known hypersensitivity) were excluded from this intervention but were followed up as per
their initial consent. Patients with CD4 cell counts above 200/μL were followed without sec-
ondary prophylaxis.
Fig 1. Follow-up period flow diagram. The maximum follow-up time was one year from initiation of VL treatment. However, patients
only entered the cohort study on achieving negative parasitology. Hence, in general, patients had less than one year of follow-up in the
cohort study.
https://doi.org/10.1371/journal.pntd.0007132.g001
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Pentamidine isethionate (Pentacarinat) secondary prophylactic treatment was started one
month after the negative test of cure (completion of VL treatment). Every month, a dose of 4
mg/kg body weight of the salt reconstituted in 5 mL distilled water was re-diluted in 200 mL of
5% dextrose in saline or normal saline solution and infused over one hour with the patient in
supine position. Patients were kept in the ward during administration and observed with fre-
quent blood pressure monitoring for one hour before discharge. The blood glucose level was
monitored prior to each infusion, and other metabolic panel tests (blood sugar level, renal
function, liver function, serum electrolytes) were run every 6 months.
Patients were offered continued ART, co-trimoxazole prophylaxis and adherence counsel-
ling. Follow-up arrangements for HIV care were made at ART clinics. Blood samples for HIV
viral load were sent to a regional reference laboratory every six months. Arrangements for
ART regimen changes were made when indicated in communication with the respective ART
clinics.
Follow-up
Follow-up started on the date negative parasitology was achieved and ended 390 days (D390)
after the initiation of the first VL treatment in the preceding trial. This means that those
patients requiring more than one course of treatment to clear parasites during their VL treat-
ment, and therefore achieving negative parasitology later, were followed up for less time than
those who responded to one course of VL treatment (Fig 1). In particular, such patients would
typically have less than one year of follow up in the cohort study.
Patients eligible for pentamidine treatment were seen monthly for prophylactic treatment.
There were two pre-specified follow-up time points for all patients, regardless of pentamidine
prophylaxis; at 6 and 12 months after initiation of treatment for the current VL episode to
check on long-term outcomes. They could present for unscheduled assessments as needed
during the follow-up period (e.g. relapse, intercurrent diseases, serious adverse events (SAE)).
All SAEs, drug related adverse events (AEs) and any event that could lead to pentamidine
interruption were documented during the follow-up period but other non-serious AEs were
not systematically captured.
Outcomes
Relapse-free survival by D390 was specified in the protocol as the primary outcome of this
cohort study. Time at risk was defined as the time from negative parasitology following VL
treatment to the earliest of the following events: i) death, ii) relapse, iii) date of the D390 visit,
and iv) date last seen (in case of loss to follow-up). Relapse-free survival was defined as reach-
ing the end of the time at risk having neither died nor relapsed. Death (i) or relapse confirmed
by positive parasitology (ii) correspond to a “failure” outcome. Conversely, alive and relapse-
free at D390 (iii) or lost to follow up (iv) correspond to censoring.
Statistical methods
Relapse-free survival at one year was estimated using Kaplan-Meier methods to account for
variable time at risk in all patients and within two sub-groups; i) CD4�200 cells/μL not receiv-
ing pentamidine secondary prophylaxis and ii) CD4<200 cells/μL receiving pentamidine sec-
ondary prophylaxis. Although these groups were not defined a priori, risk factors were found
to differ substantially between them. Graphical presentation of Kaplan-Meier analyses shows
probability of failure rather than survival to illustrate timing of relapses and deaths in this
cohort.
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Poisson regression was used to investigate univariable risk factors associated with relapse or
death, again accounting for variable time at risk. This analysis was performed within the two
sub-groups mentioned above. A multivariable model was built including those factors found
to be associated with relapse or death in univariable analyses, i.e. with 95% confidence intervals
(CIs) excluding the null effect of 1. In principle a single model could be fitted to both sub-
groups by including interactions between subgroup and the risk factors. In practice, however,
this was not possible due to small cell frequencies.
Compliance to pentamidine in those who were eligible was calculated as the percentage of
patients who received all monthly treatments for which they were eligible, i.e. until relapse,
death or D390 in surviving relapse-free patients.
Safety analyses comprised of summarizing the proportion of patients experiencing SAEs,
an SAE related to pentamidine, and an AE that required discontinuation of pentamidine treat-
ment. AE is defined as any untoward medical occurrence (any unfavourable and unintended
sign, symptom or disease, including an abnormal laboratory finding) in temporal association
with the use of the investigational treatment i.e. after the start of pentamidine. Causality rela-
tion to pentamidine is based on the known AEs listed in the Summary of Product Characteris-
tics available from the manufacturer. Grading of the severity of the events was based on
Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0 [17]. For events not
described in CTCAE, severity of AE is graded as mild (symptoms that did not require addi-
tional treatment), moderate (symptoms that require additional treatment and get controlled),
severe (symptoms that require multiple treatments and may not resolve despite treatment).
The definition of SAE was according to ICH-GCP guidelines (life threatening events or events
that led to disability, hospitalization, death, or congenital anomalies).
Ethical statement
The research protocol was approved by the Ethiopian regulatory authority (Food, Medicine,
Health Care Administration and Control Authority, FMHACA), the National Research Ethics
Review Committee (NRERC), the Institutional Review Board of the University of Gondar in
Ethiopia, the Ethics Review Board of Me´decins Sans Frontières, the London School of Hygiene
and Tropical Medicine Research Ethics Committee, the Antwerp University Hospital Ethics
Committee, and the Institute of Tropical Medicine, Antwerp Institutional Review Board. All
patients were>18years old and were included into the study after written informed consent
was given. Patients received all the required treatments free of charge including treatments for
adverse events and intercurrent diseases. Food and transport support were provided.
Results
Patient description
Except for one female, all the patients were male migrant workers with a median age of 33
years. Among the 54 patients, 28 (52%) were relapse VL cases, and 27 (50%) were malnour-
ished with body mass index (BMI) < 18.5kg/m2. Most of the patients, 39 (72%), were already
on antiretroviral treatment (ART) when VL was diagnosed with 27 (50%) being on ART for
six months or more. About two-thirds had a high Leishmania parasite load (grade of +5 and
+6) at VL diagnosis. Two-thirds of the patients had previously been treated with the Ambi-
some+miltefosine combination. Overall, 50% required more than one treatment course
(Table 1). More than one course of treatment was required for 67% of patients on Ambisome
monotherapy and 40% of patients on the combination regimen. Patients who required more
than one treatment course received the same treatment twice, or at least one course of rescue
treatment (Table 2).
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Of the 54 patients who were followed up, 22 had a CD4 count�200 cells/μL at the time of
achieving negative parasitology. Of the 32 with CD4 count<200 cells/μL, 29 were started on
pentamidine prophylaxis (Table 1). The other three had a contraindication, refused to partici-
pate in the prophylaxis or withdrew before the first pentamidine infusion, and are not included
in the analysis of relapse-free survival or risk factors for relapse or death (Fig 1). One of them
required multiple VL treatments and relapsed around 4 months after parasitological cure. The
other two patients were followed up for 9 months and 12 months, respectively, without
relapse.
The type of VL (primary or relapse), Leishmania parasite load, BMI, ART status and dura-
tion and the VL treatment regimen used were comparable between those with a CD4 cell
Table 1. Characteristics of patients achieving negative parasitology at end of VL treatment and assessed for eligibility to receive pentamidine.
CD4 < 200 cells/μL and started
pentamidine
CD4� 200 cells/
μL
CD4<200 cells/μL who did not start
pentamidinea
Overall
N = 29 N = 22 N = 3 N = 54
Site Gondar 17 (59) 11 (50) 1 29 (54)
Abdurafi 12 (41) 11 (50) 2 25 (46)
Sex Female 1 (3) 0 (0) 0 1 (2)
Male 28 (97) 22 (100) 3 53 (98)
Age, years Median (IQR) 33 (27–51) 32.5 (21–46) 37 (28–42) 33 (21–51)
Relapse statusb Primary 13 (45) 11 (50) 2 26 (48)
Relapse 16 (55) 11 (50) 1 28 (52)
Parasite countc 1+ to 4+ 9 (31) 6 (27) 2 17 (31)
5+ to 6+ 20 (69) 15 (68) 0 35 (65)
Anti-retroviral treatment at VL
diagnosisd
No, or for <6 months 15 (52) 9 (41) 2 26 (48)
Receiving ART for�6
months
13 (45) 13 (59) 1 27 (50)
VL treatmente Ambisome 10 (34) 7 (32) 1 18 (33)
Ambisome+Miltefosine 19 (66) 15 (68) 2 36 (67)
Number of courses of VL
treatmentf
1 18 (62) 7 (32) 2 27 (50)
>1 11 (38) 15 (68) 1 27 (50)
BMI at negative parasitology < 18.5 kg/m2 15 (52) 10 (45) 2 27 (50)
� 18.5 kg/m2 14 (48) 12 (55) 1 27 (50)
CD4 count at negative
parasitology (cells/μL)
<50 4 (14) 0 (0) 0 4 (7)
50–99 6 (21) 0 (0) 2 8 (15)
100 to 199 19 (66) 0 (0) 1 20 (37)
200–349 0 (0) 12 (55) 0 12 (22)
�350 0 (0) 10 (45) 0 10 (19)
Median (IQR) 110 (76–151) 337 (282–425) 90 (84–146) 173 (106–
305)
Abbreviations: BMI, Body mass index; IQR, Interquartile range; VL, visceral leishmaniasis
Data are n (%) unless otherwise indicated
aThree patients with CD4 count <200cells/μL did not start pentamidine because of contraindication, refusal and early withdrawal
b, c At the time of presentation for treatment of VL episode and randomization in the previous trial; one missing value for baseline parasite count.
dOne missing value, lacking the ART start date
e Treatment allocation as part of previous trial, although depending on parasitological and clinical improvement at end of first treatment regimen, patients may have
received no further treatment, another course of the same treatment, and/or one or more courses of rescue medication.
fOne course of treatment refers to those who had parasitological cure by D29, and�2 refers to those who required treatment for 58 days or more, either as a repeat
course of the same treatment and, or one or more courses of rescue treatment.
https://doi.org/10.1371/journal.pntd.0007132.t001
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count<200/μL who started pentamidine, and those with a CD4 cell count�200/μL who did
not receive pentamidine (Table 1). Of those with low CD4 at the end of VL treatment (<200
cells/μL), 62% of patients had received only one course of VL treatment, whereas in those with
higher CD4 (�200 cells/μL), it was lower at 32%.
The percentage of patients who received all pentamidine treatments for which they were eli-
gible was 76% (Table 2).
Relapse-free survival
The Kaplan-Meier estimates of the percentage of all patients with relapse-free survival at one
year was 50% (95%CI: 35–63%); 53% (95%CI: 30–71%) in the 22 patients with CD4�200
cells/μL and 46% (95%CI: 26–63%) in the 29 patients with CD4<200 cells/μL who started
pentamidine (Fig 2). The endpoint was reached because of death in one patient in the CD4
�200 cells/μL group. In the group with CD4<200 cells/μL and on pentamidine, the endpoint
was reached because of death in three patients, and two further patients died after reaching the
endpoint due to VL relapse. If the events of interest are restricted to relapses, with pre-relapse
deaths being considered as censored, then 57% (95%CI: 33–75%) of the 22 patients with CD4
�200 cells/μL, and 54% (95%CI: 33–71%) of the 29 patients with CD4 <200 cells/μL who
started pentamidine were relapse-free at one year.
Pentamidine treatment was not interrupted or stopped due to any adverse drug reaction.
One expected SAE was reported: renal failure, considered possibly related to pentamidine that
led to death. This patient was also experiencing pyelonephritis, sepsis, VL relapse and multiple
myeloma which might have contributed to the renal failure, either directly or by toxicity of the
concomitant medications (Table 3).
Factors associated with relapse or death: CD4<200 cells/μL and on
pentamidine
Among patients with low CD4 counts (<200 cells/μL) at the time of VL cure and who started
pentamidine prophylaxis, no statistically significant risk factors for relapse or death were iden-
tified (Table 4).
Table 2. Summary table of pentamidine initiation, compliance and safety based on patient type for patients who
started pentamidine.
Patient status at baseline (D0)
Number (%) of patients Primary VL Relapse VL Total
N = 13 N = 16 N = 29
Timing of negative parasitology:
D29 (eligible for 12 treatments) 7 (54) 11 (69) 18 (62)
D58 (eligible for 11 treatments) 3 (23) 3 (19) 6 (21)
PostD58 (eligible for <11 treatments) 3 (23) 2 (13) 5 (17)
100% compliancea, n (%) 10 (77) 12 (75) 22 (76)
Experienced serious ADR, n (%)b 1 (8) 0 (0) 1 (3)
Pentamidine stopped due to ADR 0 (0) 0 (0) 0 (0)
Abbreviations: ADR–adverse drug reaction; VL–visceral leishmaniasis
aCompliance was calculated as the percentage of pentamidine treatments received out of the number of possible
pentamidine treatments that could be given before relapse, death or the end of the study.
bRenal failure occurred in one patient who developed severe infection during follow up with monthly pentamidine
which may be of multifactorial etiology.
https://doi.org/10.1371/journal.pntd.0007132.t002
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Factors associated with relapse or death: CD4�200 cells/μL without
pentamidine
In univariable analyses of patients with higher CD4 counts (�200 cells/μL) at the time of VL
cure, higher rates of relapse or death were detected in relapse cases compared to primary cases,
and in patients with normal BMI compared to low BMI (<18.5kg/m2, Table 4). Patients previ-
ously treated with the combination regimen (Ambisome+miltefosine) for the VL episode had
a lower rate of relapse or death, compared to those on Ambisome monotherapy (Table 4).
The relation between relapse-free survival and the number of treatments required to clear
parasites was also investigated. Of note, among those with CD4 cell count above 200 cells/μl at
the end of treatment, there were no relapses or deaths in the subgroup for whom one course of
Fig 2. Kaplan-Meier curve for relapse or death, for the two groups shown in Table 3: a) CD4<200 cells/μL cells and pentamidine; and b) CD4�200 cells/μL cells
without pentamidine. Overall, the median follow-up time was 0.77 years (9.2 months, range: 0.16–1.00 years). Median (range) follow-up time; CD4<200 cells/μL &
pentamidine: 0.80 years (9.6 months, 0.16–0.99 years); CD4�200 cells/μL, no pentamidine: 0.74 years (8.9 months, 0.19–1.00 years). Thus, by one year all but one of the
patients had either relapsed (n = 21), died (n = 4), or been censored (n = 25). The short vertical lines above each of the Kaplan-Meier curves shows the times at which
censoring occurred. A large proportion of patients were censored because the scheduled time of follow-up in the cohort was 390 days minus the time between initiation
of VL treatment and achieving negative parasitology (see ‘Follow-up’ subsection of Methods). This figure shows proportions while the regression analysis in Table 4 is
based on rates per person-year. The numerical values of the proportions differ from those of the rates, but the approaches are consistent and complementary, as
explained in footnote g of Table 4.
https://doi.org/10.1371/journal.pntd.0007132.g002
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treatment was sufficient to clear parasites. Moreover, such patients had all been treated with
the Ambisome+miltefosine combination. The number of relapses being zero prevents the cal-
culation of a rate ratio for the�200 cells/μL group by the end of treatment. Conversely, all
patients with CD4�200 cells/μL at the time of negative parasitology who received Ambisome
monotherapy had required more than one course of treatment to clear parasites.
In adjusted analyses, simultaneously accounting for the VL treatment regimen, relapse sta-
tus (primary vs relapse) and BMI, only relapsed patients remained significantly associated with
subsequent relapse or death (adjusted rate ratio (ARR) = 5.42, 95%CI: 1.1–25.8, Table 4).
Discussion
The treatment of VL in HIV patients is complicated by a high rate of relapse in the first year
after VL treatment [14,15]. Relapse leads to further immunosuppression, progression of HIV
disease, predisposition to a number of opportunistic infections, failure of ART and death.
Thus, it is important to comprehensively manage VL in HIV patients to ensure an effective ini-
tial treatment that is complemented by subsequent relapse prevention.
Long-term outcomes of VL in HIV patients are described in this prospective cohort study,
with the use of pentamidine secondary prophylaxis for those with CD4 cell counts <200/μL.
Parasitologically cured VL patients with HIV co-infection were followed up for one year. The
study was conducted in Northwest Ethiopia which is one of the highest HIV-VL co-infection
regions of the world. The population is largely young adult males, with relapsed VL status and
malnutrition accounting for about half of the cases respectively and patients at different time
period on ART. The results are likely to be generalizable to the rest of Ethiopia and East Africa.
The management of patients in this cohort included offering ART to all and secondary pro-
phylaxis to those with a CD4 count <200 cells/μL after achieving parasitological cure of VL.
Three-quarters of the patients had 100% compliance for the monthly pentamidine infusions.
Low CD4 count is a known risk factor for relapse of VL [15,16]. Despite this care package, sev-
eral VL relapses occurred, regardless of CD4 count at the end of VL treatment. This indicates
the possibility of other factors influencing the long-term outcomes. The one death that was
possibly related to pentamidine was due to acute renal failure in a patient with multiple co-
existing diseases that can affect renal status. The strength of the study was that, as a continua-
tion of a clinical trial, it complied with GCP, had substantial resources for intensive follow up,
which helped ensure few missing data and consequently reduced bias.
Table 3. Serious adverse events occurring during follow-up after negative parasitology.
MedDRA preferred term Intensity Exposed to pentamidine Onseta Outcome Possible relation to pentamidine
Strongyloidiasis Death Yes 32 Death No
Septic shock Death No 144 Death No
Cerebral toxoplasmosis Life threatening Yes 207 Resolved No
Plasma cell myelomab
Renal failure acuteb
Death
Death
Yes
Yes
256
256
Death
Death
No
Yes
Retroviral infection Death Yes 270 Death No
Splenic haemorrhage Life threatening Yes 275 Resolved No
Hepatitis cholestatic Life threatening Yes 303 Resolved No
Septic shock Death Yes 317 Death No
Sepsis Death Yes 355 Death No
aTime in days after negative parasitology
bTwo serious adverse event reports in the same patient
https://doi.org/10.1371/journal.pntd.0007132.t003
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The probability of relapse-free survival at one year was 50% (95% CI: 35–63%) in all
patients. One limitation of this study was that it was not adequately powered to test differences
between the two sub-groups; CD4�200 cells/μL without pentamidine versus CD4 <200 cells/
Table 4. Associations with relapse or death by strata of CD4 count and pentamidine treatment.
N Time at risk
(person-years)
Relapse or
death
(n)
Rate of relapse or death
per person-years (95%
CI)g
Unadjusted rate
ratio (95% CI)
Adjusted rate
ratio (95% CI)h
CD4<200 cells/μL & pentamidine (N = 29a) overall 29 20.2 15 0.74 (0.45, 1–23)
VL treatment before negative
parasitology (trial arm)
Ambisome 10 8.0 3 0.37 (0.12, 1.16) 1
Ambisome
+ miltefosine
19 12.1 12 0.99 (0.56, 1.74) 2.64 (0.75, 9.36)
Number of course of
treatment required
1 18 12.6 9 0.72 (0.37, 1.38) 1
>1 11 7.61 6 0.79 (0.35, 1.75) 1.10 (0.39, 3.10)
Relapse status (at
randomization)
Primary VL 13 9.65 5 0.52 (0.22, 1.24) 1
Relapse VL 16 10.5 10 0.95 (0.51, 1.77) 1.83 (0.63, 5.37)
BMI at time of negative
parasitology
<18.5 15 10.0 9 0.90 (0.47, 1.72) 1
�18.5 14 10.1 6 0.59 (0.27, 1.32) 0.66 (0.23, 1.85)
ART at VL diagnosisb Not yet receiving ART,
or for <6months
15 10.6 8 0.76 (0.38, 1.52) 1
Receiving ART for
�6months
13 9.3 6 0.65 (0.30, 1.44) 0.85 (0.30, 2.45)
Baseline parasite count 1+ to 4+ 9 7.0 3 0.43 (0.14, 1.33) 1
5+ to 6+ 20 13.2 12 0.91 (0.52, 1.60) 2.11 (0.60, 7.49)
CD4�200cells/μL & no pentamidine (N = 22c)overall 22 14.6 10 0.69 (0.37, 1.28)
VL treatment before negative
parasitology (trial arm)
Ambisomed 7 2.8 6 2.17 (0.97, 4.82) 1 1
Ambisome+miltefosine 15 11.8 4 0.34 (0.13, 0.90) 0.16 (0.04, 0.55) 0.34 (0.07, 1.72)
Number of treatment courses
required
1e 7 6.33 0 0 (-, -)
>1 15 8.24 10 1.21 (0.65, 2.26) -
Relapse status (at
randomization)
Primary 11 8.33 2 0.24 (0.06, 0.96) 1 1
Relapse 11 6.23 8 1.28 (0.64, 2.57) 5.35 (1.14, 25.2) 5.42 (1.14, 25.8)
BMI at time of negative
parasitology
<18.5 10 8.43 2 0.24 (0.06, 0.95) 1 1
�18.5 12 6.14 8 1.30 (0.65, 2.61) 5.50 (1.17, 25.9) 3.18 (0.44, 22.7)
ART at VL diagnosis Not yet receiving ART,
or for <6m
9 5.32 4 0.75 (0.28, 2.00) 1
Receiving ART for�6m 13 9.25 6 0.65 (0.29, 1.44) 0.86 (0.24, 3.05)
Baseline parasite countf 1+ to 4+ 6 4.4 1 0.23 (0.03, 1.61) 1
5+ to 6+ 15 9.2 9 0.98 (0.51, 1.89) 4.34 (0.55, 34.3)
Abbreviations: ART, Antiretroviral therapy; BMI, Body mass index; CI, confidence interval; VL, visceral leishmaniasis
aOf whom 12 relapsed and 3 died (15 with the endpoint).
bOne missing value, lacking the ART start date
cOf whom 9 relapsed and 1 died (10 with the endpoint).
dAll these patients required more than one course of treatment (either a repeat regimen of the same treatment or rescue)
eAll who cleared parasites after one course of treatment were on Ambisome+Miltefosine
fOne missing value
gExpressed as rates per person-year. The numerical values of the rates differ from those of the proportions in Fig 2 but the approaches are consistent and
complementary. For example, converting the rate here (0.74 per person-year) to a proportion surviving relapse-free at one year gives e-0.74/year × 1 year = 0.48, very similar
to the 0.46 from the Kaplan-Meier analysis in Fig 2.
hAdjusted RRs from a multivariable model that includes all factors associated with relapse or death in univariable analyses; after adjustment, only patient type remains
associated with rate of relapse or death. No univariable associations for patients with CD4 <200 cells/μl who started pentamidine
https://doi.org/10.1371/journal.pntd.0007132.t004
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μL and receiving pentamidine prophylaxis. Another limitation was that the allocation of pent-
amidine was dependent on CD4 count which complicates the interpretation of the results and
does not allow for unbiased estimation of an overall effect of pentamidine prophylaxis, or an
overall effect of CD4 count. Interestingly, comparable probabilities of relapse-free survival
were seen in the two groups, 53% (95%CI 30–71%) and 46% (95%CI 26–63%) respectively. A
direct comparison of the two groups (patients with CD4<200 given prophylaxis and patients
with CD4>200 without prophylaxis) based on a hypothesis of a difference was not included in
our study as we may not expect a difference between these two groups if pentamidine can
reduce the risk of relapse or death due to low CD4, bringing the risk more in line with risk in
those with higher CD4 and not on pentamidine, and we propose this as a hypothesis. Accord-
ing to previous reports, 60–70% of VL cases with HIV co-infection and on ART relapse within
one year in the absence of secondary prophylaxis, the relapse rate being higher with a lower
CD4 count [14,15]. The few existing reports on the use of secondary prophylaxis showed a
relapse-free survival rate at one year ranging from 40–80% and a relapse rate among patients
without secondary prophylaxis of 50–100% [11,18–21]. Most of these studies were case series
studies from a region with L. infantum transmission, using different drugs and different fol-
low-up patterns.
In a recently conducted interventional cohort at the same study sites in Ethiopia, primary,
relapse and past VL cases were enrolled. Pentamidine was given to those who achieved nega-
tive parasitology for the VL episode if their CD4 cell count was<200 cells/μL, and to all relapse
cases regardless of CD4 count. The relapse-free survival rate at one year in all patients was 71%
[16]. Looking more in depth at subgroups, the relapse-free survival rate for patients with CD4
<200 cells/μL (n = 45) in this previous study was 68% (95%CI: 52%-80%) and in those with
CD4�200 cells/μL (n = 12), it was 82% (95%CI: 45%-95%), with up to 12 months of pentami-
dine prophylaxis. There was no apparent difference in relapse-free survival observed in the
groups with CD4<200 cells/μL between the two studies, based on the overlap between the
95% confidence intervals around relapse-free survival in each study.
The potential benefit of pentamidine amongst patients in the current study can be hypothe-
sized to result from pentamidine treatment reducing the rate of relapse amongst those more
likely to otherwise do so, to a rate closer to that observed in patients with a higher CD4 count.
Although the use of secondary prophylaxis reduced the risk of relapse, there was still a notably
high number of patients who continued to relapse in both groups (CD4 <200 and CD4�200
cells/μL). There are earlier reports showing relapse at higher CD4 count and also with second-
ary prophylaxis use [6,11].
Multiple factors may play a role in the risk of VL relapse. In this study, CD4 count, duration
on ART, VL relapse status (primary vs relapse), the Leishmania parasite load at diagnosis, the
antileishmanial treatment regimen (Ambisome monotherapy vs Ambisome+miltefosine com-
bination), the duration of VL treatment and BMI were evaluated. In the group of patients with
CD4 cell count <200/μL and receiving pentamidine, no additional independent risk factors
were found to be associated with an increased rate of relapse. There is a need for additional,
adequately powered studies to assess the risk factors for persistent immunosuppression in
these patients. VL disease while on ART and low CD4 count is a WHO AIDS-defining illness
and an indicator of advanced HIV disease and possibly undiagnosed ART failure [22,23]. For
patients with profound immunodeficiency, ART, anti-Leishmania combination therapy and
secondary prophylaxis seem insufficient to prevent relapse. The high relapse rate among these
groups of patients indicates the need to explore other treatment modalities. These can be more
frequent and/or higher doses of the prophylaxis or other interventions that can rapidly im-
prove immunity [24]. Serum level of pentamidine was not checked in the study and the opti-
mal prophylaxis dose is not known. Due to the differences in the formulation of pentamidine,
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the dose used in this study might be lower [25]. Beyond that, the goal should be for early detec-
tion and management of VL before profound immune deficiency sets in [26].
In the group of patients who had a CD4 cell count above 200/μl at the end of VL treatment
(stable on ART), past history of VL treatment (relapse) was an independent risk factor for sub-
sequent relapse, as has previously been observed [15,27]. The current study reconfirms that
patients with a previous history of relapse have a higher risk of relapse regardless of their CD4
cell count, adjusted rate ratio of 5.42 (1.14, 25.8). The small sample size in this group did not
allow for further breakdown of the CD4 level and subgroup analysis. However, the findings
indicate that CD4 level recommendation for secondary prophylaxis has to be re-visited and
higher cut-off values be recommended [28].
Although the study was not adequately powered for a pre-specified magnitude of rate ratio,
it is plausible to hypothesize a worse prognosis for patients whose VL episodes were hard-to-
treat. Hard-to-treat patients are likely to include those who develop VL while on ART for
more than 6 months, have a persistently low CD4 count (<200 cells/μL) after VL treatment
(advanced HIV disease), those who require longer treatment to cure VL, those with treatment
failure for a combination regimen and previous history of VL treatment [15]. Because CD4
recovery can take time, those who received longer VL treatment (negative parasitology at or
after D58) were likely to achieve CD4 cell counts above 200/μL and thus become ineligible for
secondary prophylaxis in this study, while they still fall in the category of hard-to-treat
patients. It could be hypothesized that those patients would have benefited from the secondary
prophylaxis, hence avoiding some of the observed relapses in the group with the higher CD4
cell count. In this study 50% of those with CD4 cell count�200cells/μl were relapsed patients
who might have benefited from secondary prophylaxis.
Patients who require prolonged initial VL treatment (>1 month) might be those with
advanced disease and high initial parasite load, or those receiving less effective initial treatment
(e.g. Ambisome monotherapy). A highly effective initial VL treatment regimen (e.g. combina-
tion therapy) seems a more favorable approach, especially for hard-to-treat VL patients.
Likewise, faster parasitological cure of VL and CD4 recovery�200 cells/μL (cure by D29)
can be a sign of mild disease and relatively well-preserved immunity. Of the seven patients
who responded to initial treatment (parasite clearance) by D29 and had CD4 count�200
cells/μL (thus without pentamidine prophylaxis), none relapsed or died. Although based on a
very small number of patients, this could suggest that secondary prophylaxis may not be a pri-
ority for patients who respond to one course of treatment and achieve a CD4 level�200 cells/
μL. This might be related to early diagnosis of VL in ART stable patients. On the other hand,
the decision for secondary prophylaxis may need to be based on the CD4 level at the time of
VL diagnosis rather than after VL treatment.
In general, we have observed that the long-term outcome of VL in HIV patients is affected
by multiple factors–importantly the level of immunity, history of VL treatment and the use of
secondary prophylaxis. While a clear trend of benefit from the secondary prophylaxis is
observed among those with low immunity, it should be noted that the treatment of these
patients requires a multifactorial approach. Effective ART is a crucial component. Although
the management of HIV included ART provision, clinical and CD4 cell monitoring; regular
viral load determination was not possible due to the limited services available in the country
during the study period and the delayed provision of results. The available data suggest that
not all patients were on successful ART treatment and only a few had second line ART (S1, S2
and S3 Tables). Sustainable treatment of HIV-related opportunistic infection without effective
ART is impossible. Integration of HIV treatment within the treatment programs of endemic
opportunistic diseases is important for effective disease control [8,29]. HIV viral load results
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are important for patient management decisions and facilities in high endemic regions need to
be upgraded with such services.
In conclusion, the VL relapse rate in HIV co-infected patients is high irrespective of CD4
level. Secondary prophylaxis with pentamidine was found to be safe except in patients with
risk factors for renal failure and could help prolong the disease-free survival of those with a
CD4 count below 200cells/μL to a rate comparable to that for patients with CD4 count above
200 cells/μL and not receiving secondary prophylaxis. There are studies supporting its effec-
tiveness and safety from both L. donovani and L. infantum regions [12,16,30,31]. However, the
available data to date are based on small numbers of patients and from non-randomized stud-
ies, and are therefore below the ideal level of evidence needed to recommend implementation.
Taking into consideration the high mortality and morbidity of VL-HIV co-infection and the
urgent need for better management, we strongly recommend the use of secondary prophylaxis
as an integral part of VL management in HIV. Priority cases for secondary prophylaxis are
patients whose CD4 cell count remain <200/μL after effective VL treatment and those with a
history of VL treatment (VL relapses). A monthly infusion of pentamidine is a suitable option
in terms of feasibility and safety, except for patients with renal diseases. Future prospective
research studies could investigate alternative prophylactic regimens, different dosing and fre-
quency to improve relapse-free survival, alongside new treatment approaches for hard-to-treat
patients.
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